糖尿病药物市场按药物类别、给药途径、糖尿病类型、药物来源和分销管道划分－2025-2032 年全球预测

预计到 2032 年糖尿病药物市场将成长至 1,172.5 亿美元，复合年增长率为 6.10%。

简明介绍不断发展的糖尿病药物格局，结合科学进步、获取动态和商业性需求

糖尿病治疗领域正经历快速变革，这得益于药物类别、给药方式和商业策略的突破。过去几年，临床进展重塑了治疗模式，而患者偏好和支付方压力也同时推动製造商在价值、便利性和依从性方面进行创新。因此，从生物製药公司高阶主管到分销合作伙伴，各利益相关人员正在重新调整其优先事项，以确保临床疗效与实际可及性和成本的一致性。

本导言将读者置于这些汇聚力量的更广泛背景中，强调治疗创新与供应链和报销结构性转变之间的相互作用。接下来的叙述将探讨科学和商业化的变革性转变，评估诸如关税变化等具有跨境影响的政策意涵，并将细分和区域动态转化为可供领导者参考的可行见解。其目标是为制定将科学机会与商业和商业性现实相结合的策略提供综合的、基于证据的基础。

科学进步、数位健康整合和供应链弹性如何重塑糖尿病药物的临床和商业策略

糖尿病格局正被几股相互依存的力量改变，这些力量正在改变研发重点、临床实务和商业模式。肠促胰岛素生物学和胜肽疗法的进展正在重新定义治疗流程，扩展治疗套件，并鼓励现有企业投资下一代分子和递送技术。同时，数位健康解决方案和远端监控正在提升数据主导的依从性计划，并提升真实世界证据在影响支付方覆盖范围和指南采纳方面的作用。

对供应链韧性和区域製造的投资日益成为策略重点，企业正在重新评估其采购布局，以降低业务中断的风险。策略合作伙伴关係和平台授权协议正在加速发展，使小型创新企业能够在无需巨额资本支出的情况下实现规模扩张，同时使大型企业能够拓展产品线。这种转变不仅加剧了竞争，还透过以患者为中心的医疗服务、一体化照护模式以及注重长期疗效而非一次性干预的差异化价值主张，创造了差异化的提案。

评估近期关税调整和贸易政策转变如何重塑 2025 年糖尿病价值链的采购、定价和供应链策略

2025年贸易和关税制度的政策变化将为糖尿病生态系统中的製造商、经销商和付款人带来新的复杂性，促使他们重新评估采购、定价和库存策略。关税调整可能会增加成品药和原料药的到岸成本，迫使采购团队重新评估供应商选择，多元化供应基础，并更多地依赖区域製造合作伙伴以降低风险。这些决策反过来将影响与付款人和采购机构的合约动态，因为企业的目标是保持价格竞争力，同时保护利润率和供应的连续性。

除了直接的成本效应外，关税引发的供应链反应可能会加速区域对製造产能的投资，并影响长期竞争地位。法规合规性、清关时限和文件要求已成为供应链团队的关键领域。积极模拟关税情景并实施灵活采购、多产地筹资策略和近岸製造方案的公司将能够更好地吸收政策衝击并保持跨区域市场进入。

多维细分洞察，结合药物类别、给药途径、病患类型、地理来源和分销管道，指导临床和商业优先事项

细分阐明了临床需求、商业性机会和营运要求的交汇点，从而明确策略规划。药物类别包括Amylin类似物、GLP-1受体促效剂、胰岛素和口服抗糖尿病药物 (OAD)，胰岛素进一步分为长效和短效。胜肽类肠促胰岛素疗法注重药效持续时间和代谢益处，而胰岛素製剂则需要差异化的递送和与製剂动力学相关的低温运输考量。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章 市场洞察

• 在第 2 型糖尿病管理中，越来越多地采用 SGLT2 抑制剂来降低心肾风险
• GLP-1受体促效剂在第2型糖尿病治疗中用于减重和血糖控制的应用迅速扩大
• 生物相似药胰岛素产品的兴起正在改变全球糖尿病护理的定价和市场进入
• 将持续血糖监测数据与胰岛素帮浦结合，推动个人化糖尿病治疗策略
• 口服胰岛素输送平台的出现旨在提高患者依从性并减少对注射的依赖
• 增加真实世界证据的使用，以支持糖尿病药物开发平臺中联合治疗的核准
• 实施人工智慧胰岛素剂量演算法，透过预测分析增强血糖管理
• 开发针对微生物标靶药物作为解决糖尿病代谢途径的新型辅助性治疗

第六章：2025年美国关税的累积影响

第七章：人工智慧的累积影响，2025年

第 8 章：糖尿病药物市场（依药物类别）

• Amylin 类似物
• GLP-1受体促效剂
• 胰岛素
  • 长效
  • 短效
• 口服抗糖尿病药物（OAD）

9. 糖尿病药物市场（依给药途径）

• 吸入
• 注射
• 口服

第 10 章糖尿病药物市场（依糖尿病类型）

• 1型糖尿病
• 2型糖尿病

第 11 章糖尿病药物市场（依药物来源）

• 品牌药
• 学名药

第十二章糖尿病药物市场（依分销管道）

• 家庭医疗保健
• 医院药房
• 网路药局
• 零售药局

第 13 章：糖尿病药物市场（按地区）

• 美洲
  • 北美洲
  • 拉丁美洲
• 欧洲、中东和非洲
  • 欧洲
  • 中东
  • 非洲
• 亚太地区

第十四章糖尿病药物市场（依类别）

• ASEAN
• GCC
• EU
• BRICS
• G7
• NATO

第 15 章 各国糖尿病药物市场

• 美国
• 加拿大
• 墨西哥
• 巴西
• 英国
• 德国
• 法国
• 俄罗斯
• 义大利
• 西班牙
• 中国
• 印度
• 日本
• 澳洲
• 韩国

第十六章竞争格局

• 2024年市占率分析
• 2024年FPNV定位矩阵
• 竞争分析
  • Novo Nordisk A/S
  • Eli Lilly and Company
  • Sanofi SA
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer Inc.
  • Johnson & Johnson
  • Bayer AG

The Diabetes Drugs Market is projected to grow by USD 117.25 billion at a CAGR of 6.10% by 2032.

A succinct orientation to the evolving diabetes therapeutics landscape that connects scientific advances, access dynamics, and commercial imperatives

The diabetes therapeutics landscape is experiencing a period of concentrated evolution driven by breakthroughs in drug classes, delivery modalities, and commercial strategies. Over the past several years clinical advances have reshaped treatment paradigms, while patient preferences and payer pressures have simultaneously driven manufacturers to innovate on value, convenience, and adherence. As a result, stakeholders from biopharma executives to distribution partners are recalibrating priorities to reconcile clinical effectiveness with practical access and cost considerations.

This introduction situates readers within the broader context of these converging forces. It emphasizes the interplay between therapeutic innovation and structural shifts in supply chains and reimbursement. The narrative that follows explores transformative shifts across science and commercialization, assesses policy impacts such as tariff changes with cross-border implications, and translates segmentation and regional dynamics into practical insights for leaders. The goal is to provide an integrated, evidence-based foundation for strategy development that aligns scientific opportunity with operational and commercial realities.

How converging scientific advances, digital health integration, and supply chain resilience are reshaping clinical practice and commercial strategies across diabetes therapeutics

The diabetes landscape is being transformed by several interdependent forces that are altering development priorities, clinical practice, and commercial models. Advances in incretin biology and peptide therapeutics have redefined treatment algorithms and expanded the therapeutic toolkit, prompting incumbents to invest in next-generation molecules and delivery technologies. Concurrently, digital health solutions and remote monitoring have elevated the role of data-driven adherence programs and real-world evidence in shaping payer coverage and guideline adoption.

Supply chain resilience and regional manufacturing investments are increasingly strategic priorities, with companies re-evaluating sourcing footprints to reduce exposure to disruptions. Strategic collaborations and platform licensing deals are accelerating, enabling smaller innovators to scale without extensive capital outlay while allowing larger players to broaden their pipelines. These shifts heighten competition but also create windows for differentiation through patient-centric delivery formats, integrated care models, and differentiated value propositions focused on long-term outcomes rather than episodic interventions.

Assessing how recent tariff adjustments and trade policy shifts in 2025 have reconfigured sourcing, pricing, and supply chain strategies across the diabetes value chain

Policy shifts in trade and tariff regimes in 2025 have introduced new complexities for manufacturers, distributors, and payers in the diabetes ecosystem, prompting reappraisals of sourcing, pricing, and inventory strategies. Tariff adjustments can elevate landed costs for finished formulations and active pharmaceutical ingredients, prompting procurement teams to revisit supplier selection, diversify supply bases, and increase reliance on regional manufacturing partners to mitigate exposure. In turn, these decisions influence contracting dynamics with payers and procurement bodies as firms aim to preserve price competitiveness while protecting margin and supply continuity.

Beyond direct cost effects, tariff-driven supply chain responses can accelerate local invest-ment in manufacturing capacity, influencing long-term competitive positioning. Regulatory compliance, customs clearance timelines, and documentation requirements have become focal areas for supply chain teams, as delays can propagate downstream to hospital pharmacies and outpatient access points. Companies that proactively model tariff scenarios and implement flexible sourcing, multi-origin procurement strategies, and near-shore manufacturing options will be better positioned to absorb policy shocks and sustain market access across geographies.

Multidimensional segmentation insights that align drug class, administration route, patient type, origin, and distribution channel to prioritize clinical and commercial priorities

Segmentation drives clarity in strategic planning by revealing where clinical need, commercial opportunity, and operational requirements intersect. Based on Drug Class, the landscape includes Amylin Analogs, GLP-1 Receptor Agonists, Insulin, and Oral Antidiabetic Drugs (OADs), with Insulin further delineated into Long Acting and Short-Acting categories. This framing highlights divergent development pathways: peptide-based incretin therapies emphasize durability and metabolic benefits, whereas insulin segments require differentiated delivery and cold-chain considerations tied to formulation kinetics.

Based on Route Of Administration, therapies span Inhalation, Injectable, and Oral formats, each carrying distinct adherence profiles, device development imperatives, and regulatory pathways. Delivery route choices drive patient experience and real-world persistence, and therefore directly influence positioning and reimbursement conversations. Based on Diabetes Type, the pipeline and product mix serve both Type 1 Diabetes and Type 2 Diabetes populations; clinical needs and care settings vary substantially between these cohorts, necessitating tailored engagement strategies for providers and payers.

Based on Drug Origin, offerings are categorized as Branded Drugs and Generic Drugs, a distinction that affects lifecycle management, price sensitivity, and competitive dynamics. Branded innovators focus on differentiation through outcomes and ancillary services, while generic entrants concentrate on cost leadership and supply continuity. Based on Distribution Channel, products reach patients through Home Healthcare, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy routes, and each channel imposes unique logistics, reimbursement, and patient education requirements. When these segmentation lenses are combined, they create a multi-dimensional view of opportunity and risk that supports prioritization of assets, channel strategies, and investment decisions.

Regional dynamics and differentiated access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy and supply choices

Regional dynamics continue to shape competitive agendas, regulatory strategies, and manufacturing footprints as diabetes care evolves across diverse healthcare ecosystems. In the Americas, market dynamics emphasize payer negotiations, integrated care pathways, and innovation adoption in both primary care and specialist settings. Reimbursement approaches and the role of pharmacy benefit managers impact formulary positioning and patient access programs, creating an environment where evidence of long-term outcomes and cost-effectiveness can unlock preferential placement.

The Europe, Middle East & Africa region offers heterogenous regulatory landscapes and procurement models, with some countries emphasizing centralized tendering and others relying on decentralized reimbursement decisions. This diversity requires tailored regulatory strategies, localized evidence packages, and flexible pricing models to navigate public procurement, hospital purchasing, and national health system priorities. Similarly, Asia-Pacific presents a mix of high-growth demand centers, price-sensitive markets, and rapidly expanding domestic manufacturing capability. Local production and regulatory endorsement can significantly accelerate market entry, while cross-border trade policies and regional partnerships influence supply chain resilience and competitive dynamics. Across all regions, the interplay between local regulation, payer structure, and manufacturing location informs go-to-market sequencing and long-term investment choices.

How scientific pipeline depth, strategic alliances, and manufacturing integration are reshaping competitive positions and value propositions among leading diabetes players

Competitive dynamics among leading companies reflect a blend of deep scientific pipelines, strategic alliances, and manufacturing control. Established pharmaceutical firms continue to invest in lifecycle extensions, delivery innovations, and outcome-driven positioning to protect premium segments. Meanwhile, biotech players and specialty developers focus on breakthrough mechanisms and differentiated benefit-risk profiles that attract partnership interest and licensing arrangements.

Across the sector, companies are prioritizing vertical integration for critical components such as peptide synthesis and cold-chain logistics to reduce exposure to supply disruptions. Strategic alliances frequently couple small-molecule or biologic innovators with larger commercialization partners to accelerate scale and market access. Additionally, the rise of biosimilars and generics in key insulin segments has intensified competition on price and supply security, prompting incumbent companies to emphasize service-based differentiation, patient support programs, and bundled care solutions to sustain brand value.

Practical, cross-functional strategic moves that align R&D priorities, supply diversification, payer engagement, and digital integration to secure competitive advantage

Industry leaders must pursue a coordinated set of actions to translate technological and policy shifts into sustainable advantage. First, companies should align R&D priorities with unmet clinical needs and payer evidence requirements, investing in endpoints that demonstrate durable outcomes and cost offsets over time. In parallel, portfolio managers should evaluate route-of-administration innovations and device synergies that can meaningfully enhance adherence and differentiate offerings in crowded therapeutic classes.

Operationally, firms need to diversify sourcing and accelerate regional manufacturing capabilities to hedge against tariff and trade volatility while shortening lead times for critical ingredients. Commercial teams should deepen engagement with payers and health systems to co-design value agreements and outcomes-based contracts that reflect real-world performance. Moreover, cross-functional investments in digital adherence platforms and remote monitoring should be scaled to support clinical claims with real-world data and strengthen patient retention. Finally, organizations should pursue selective partnerships and licensing arrangements to access complementary capabilities rapidly, balancing internal development with external innovation to maintain agility.

A transparent mixed-methods research approach integrating expert primary interviews, secondary literature review, and scenario-based triangulation to ensure actionable insights

The research approach combines structured primary research with rigorous secondary analysis and methodological triangulation to ensure robustness and practical relevance. Primary inputs included interviews with clinical experts, supply chain leaders, commercial executives, and payers to capture forward-looking perspectives on therapeutic adoption, reimbursement dynamics, and operational priorities. These qualitative insights were triangulated with regulatory filings, peer-reviewed clinical literature, and company disclosures to validate technical claims and development trajectories.

Data synthesis employed scenario analysis to test supply chain and policy sensitivities, while thematic coding distilled recurring strategic imperatives across stakeholders. Quality controls included cross-validation of interview findings with public filings and expert peer review to mitigate bias. Limitations include variability in regional reporting standards and the evolving nature of policy environments; the methodology addresses these by emphasizing scenario-based guidance rather than prescriptive numeric forecasts and by documenting assumptions that underpin strategic implications.

Concluding synthesis of strategic imperatives that combine clinical differentiation, operational resilience, and payer-aligned value to secure long-term positioning

In summary, the diabetes therapeutics domain is at an inflection point where scientific innovation, patient-centered delivery, and policy dynamics intersect to redefine competitive and operational priorities. Stakeholders who integrate deep clinical differentiation with resilient supply strategies and payer-aligned value propositions will be best positioned to capture sustainable advantages. The dual focus on real-world evidence and patient experience will increasingly determine which therapies achieve broad adoption and preferred positioning within constrained reimbursement environments.

Leaders should view the current environment as an opportunity to accelerate investments in differentiated delivery formats, regional manufacturing, and outcome-focused engagements. Those that act decisively to align clinical development with commercial access imperatives and operational resilience will create defensible positioning in an increasingly complex global landscape.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Rising adoption of SGLT2 inhibitors for cardio-renal risk reduction in type 2 diabetes management
• 5.2. Rapid expansion of GLP-1 receptor agonists utilization for weight loss and glycemic control in type 2 diabetes therapy
• 5.3. Proliferation of biosimilar insulin products reshaping pricing dynamics and market access in global diabetes care
• 5.4. Integration of continuous glucose monitoring data with insulin pumps driving personalized diabetes treatment strategies
• 5.5. Emergence of oral insulin delivery platforms aiming to improve patient adherence and reduce injection dependency
• 5.6. Increasing use of real-world evidence supporting combination therapy approvals in diabetes drug development pipelines
• 5.7. Adoption of AI-driven insulin dosing algorithms enhancing glycemic management through predictive analytics insights
• 5.8. Development of microbiome-targeted agents as novel adjunctive therapies addressing metabolic pathways in diabetes

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Drugs Market, by Drug Class

• 8.1. Amylin Analogs
• 8.2. GLP-1 Receptor Agonists
• 8.3. Insulin
  • 8.3.1. Long Acting
  • 8.3.2. Short-Acting
• 8.4. Oral Antidiabetic Drugs (OADs)

9. Diabetes Drugs Market, by Route Of Administration

• 9.1. Inhalation
• 9.2. Injectable
• 9.3. Oral

10. Diabetes Drugs Market, by Diabetes Type

• 10.1. Type 1 Diabetes
• 10.2. Type 2 Diabetes

11. Diabetes Drugs Market, by Drug Origin

• 11.1. Branded Drugs
• 11.2. Generic Drugs

12. Diabetes Drugs Market, by Distribution Channel

• 12.1. Home Healthcare
• 12.2. Hospital Pharmacy
• 12.3. Online Pharmacy
• 12.4. Retail Pharmacy

13. Diabetes Drugs Market, by Region

• 13.1. Americas
  • 13.1.1. North America
  • 13.1.2. Latin America
• 13.2. Europe, Middle East & Africa
  • 13.2.1. Europe
  • 13.2.2. Middle East
  • 13.2.3. Africa
• 13.3. Asia-Pacific

14. Diabetes Drugs Market, by Group

• 14.1. ASEAN
• 14.2. GCC
• 14.3. European Union
• 14.4. BRICS
• 14.5. G7
• 14.6. NATO

15. Diabetes Drugs Market, by Country

• 15.1. United States
• 15.2. Canada
• 15.3. Mexico
• 15.4. Brazil
• 15.5. United Kingdom
• 15.6. Germany
• 15.7. France
• 15.8. Russia
• 15.9. Italy
• 15.10. Spain
• 15.11. China
• 15.12. India
• 15.13. Japan
• 15.14. Australia
• 15.15. South Korea

16. Competitive Landscape

• 16.1. Market Share Analysis, 2024
• 16.2. FPNV Positioning Matrix, 2024
• 16.3. Competitive Analysis
  • 16.3.1. Novo Nordisk A/S
  • 16.3.2. Eli Lilly and Company
  • 16.3.3. Sanofi S.A.
  • 16.3.4. AstraZeneca PLC
  • 16.3.5. Boehringer Ingelheim International GmbH
  • 16.3.6. Merck & Co., Inc.
  • 16.3.7. Novartis AG
  • 16.3.8. Pfizer Inc.
  • 16.3.9. Johnson & Johnson
  • 16.3.10. Bayer AG

LIST OF FIGURES

• FIGURE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
• FIGURE 2. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
• FIGURE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
• FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2024 VS 2032 (%)
• FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2032 (%)
• FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
• FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 13. AMERICAS DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 14. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 15. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 16. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 17. EUROPE DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 18. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 19. AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 22. ASEAN DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 23. GCC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 24. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 25. BRICS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 26. G7 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 27. NATO DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
• FIGURE 29. DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 30. DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

• TABLE 1. DIABETES DRUGS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
• TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2025-2032 (USD MILLION)
• TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2025-2032 (USD MILLION)
• TABLE 35. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 37. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 39. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY REGION, 2025-2032 (USD MILLION)
• TABLE 41. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY GROUP, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY GROUP, 2025-2032 (USD MILLION)
• TABLE 43. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 45. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 47. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2025-2032 (USD MILLION)
• TABLE 49. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 51. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 53. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 55. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 57. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 59. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
• TABLE 61. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 63. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 65. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 67. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 69. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 71. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 73. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2025-2032 (USD MILLION)
• TABLE 75. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 77. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 79. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 81. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 83. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 85. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 87. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2025-2032 (USD MILLION)
• TABLE 89. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 91. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 93. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 95. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 97. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 99. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 101. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 103. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 105. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 107. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 109. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 111. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 113. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2032 (USD MILLION)
• TABLE 115. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 117. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 119. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
• TABLE 121. AMERICAS DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 122. AMERICAS DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 123. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 124. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 125. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 126. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 127. AMERICAS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 128. AMERICAS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 129. AMERICAS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 130. AMERICAS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 131. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 132. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 133. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 134. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 135. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 136. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 137. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 138. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 139. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 140. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 141. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 142. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 143. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 144. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 145. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 146. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 147. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 148. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 149. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 150. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 151. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 152. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 153. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 154. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 155. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 156. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 157. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 158. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 159. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 160. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 161. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 162. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 163. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
• TABLE 164. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
• TABLE 165. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 166. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 167. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 168. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 169. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 170. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 171. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 172. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 177. EUROPE DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 178. EUROPE DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 179. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 180. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 181. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 182. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 183. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 184. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 185. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 186. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 187. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 188. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 189. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 190. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 191. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 192. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 193. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 194. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 195. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 196. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 197. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 198. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 199. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 200. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 201. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 202. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 203. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 204. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 205. AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 206. AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 207. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 208. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 209. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 210. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 211. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 212. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 213. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 214. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 215. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 216. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 217. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 218. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 219. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 220. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 221. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 222. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 223. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 224. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 225. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 226. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 227. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 228. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 229. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 230. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 231. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 232. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 233. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
• TABLE 234. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
• TABLE 235. ASEAN DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 236. ASEAN DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 237. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 238. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 239. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 240. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 241. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 242. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 243. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 244. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 245. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 246. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 247. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 248. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 249. GCC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 250. GCC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 251. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 252. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 253. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 254. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 255. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 256. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 257. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 258. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 259. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 260. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 261. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 262. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 263. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 264. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 265. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 266. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 267. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 268. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 269. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 270. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 271. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 272. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 273. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 274. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 275. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 276. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 277. BRICS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 278. BRICS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 279. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 280. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 281. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 282. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 283. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 284. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 285. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 286. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 287. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 288. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 289. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 291. G7 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 292. G7 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 293. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 294. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 295. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 296. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 297. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 298. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 299. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 300. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 301. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 302. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 303. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 304. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 305. NATO DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 306. NATO DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 307. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 308. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 309. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 310. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 311. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 312. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 313. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 314. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 315. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 316. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 317. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 318. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 319. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 320. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
• TABLE 321. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 322. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 323. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 324. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 325. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 326. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 327. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 328. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 329. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 330. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 331. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 332. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 333. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 334. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 335. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 336. CANADA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 337. CANADA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 338. CANADA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 339. CANADA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 340. CANADA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 341. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2024 (USD MILLION)
• TABLE 342. CANADA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025-2032 (USD MILLION)
• TABLE 343. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 344. CANADA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
• TABLE 345. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
• TABLE 346. MEXICO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
• TABLE 347. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2024 (USD MILLION)
• TABLE 348. MEXICO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2025-2032 (USD MILLION)
• TABLE 349. MEXICO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
• TABLE 350. MEXICO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
• TABLE 351. MEXICO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2024 (USD MILLION)
• TABLE 352. MEXICO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025-2032 (USD MILLION)
• TABLE 353. MEXICO DIABETES DRUGS